Overview

Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the efficacy and safety of two staggered dose levels of inhaled once daily AZD5423 or twice daily budesonide for 12 weeks in COPD patients on a background therapy of formoterol.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide
Formoterol Fumarate